Pozen Sues Par Pharmaceutical Over Migraine ANDA

Law360, New York (November 17, 2008, 12:00 AM EST) -- Pozen Inc., a North Carolina-based pharmaceutical company specializing in pain medication, has sued Par Pharmaceutical Inc., for seeking regulatory approval of a generic version of Pozen's patented migraine treatment Treximet.

The complaint, filed in the U.S. District Court for the Eastern District of Texas on Friday, claims New Jersey-based Par Pharmaceutical infringed three Pozen patents when it filed an abbreviated new drug application with the U.S. Food and Drug Administration for a generic form of Treximet, which consists of 85 mg of sumatriptan and 500 mg...
To view the full article, register now.